GlaxoSmithKline PLC

GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
  • TickerGSK
  • ISINGB0009252882
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom

Analysts

Damien Conover

Morningstar | GSK Updated Forecasts and Estimates from 17 Jan 2019

GlaxoSmithKline and Pfizer announced the creation of a consumer healthcare joint venture (followed by the potential separation of the entity), which we expect will drive better synergies and unlock value for both companies, but we don't expect any significant changes to our fair value estimates for either company. The companies expect close to GBP 500 million in cost synergies, which seems reasonable. Additionally, we believe the potential separation of the new joint venture could unlock value for both Pfizer and Glaxo, as consumer healthcare companies trade at higher valuation multiples than ...

GlaxoSmithKline plc: Update following affirmation of A2 issuer rating

GlaxoSmithKline's credit metrics will remain weak for a prolonged period of time following acquisition of Tesaro as uncertainty around future business profile increases

Eric Le Berrigaud

GLAXOSMITHKLINE: GSK makes long-awaited move to split the group in two parts | NEUTRAL | 1660p vs. 1620p

GLAXOSMITHKLINE - NEUTRAL | 1660p vs. 1620p (+10%) GSK makes long-awaited move to split the group in two parts The future exit of CHC is a good way to deleverage Pharma A positive move but some concerns remain An accretive deal to partially offset dilution from Tesaro Back to our figures before Tesaro. Slight increase of our FV

Jean Sassus ...
  • Martial Descoutures
  • Pierre Corby
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/20/2018

Following the Oddo BHF cognac seminar held in November 2018, we are adopting a cautious view of the cognac market. After a clear acceleration in growth for the past two years, the market seems increasingly risky in the short term and its downturn would have clear repercussions on earnings growth for all spirits groups. Even though cognac is a prized asset for them, in that it guarantees a high valuation for the long term due to its scarcity value and high-end profile, we reiterate our...

Jean Sassus ...
  • Martial Descoutures
  • Pierre Corby
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 20/12/2018

...

GlaxoSmithKline plc: Update following affirmation of A2 issuer rating

GlaxoSmithKline's credit metrics will remain weak for a prolonged period of time following acquisition of Tesaro as uncertainty around future business profile increases

GlaxoSmithKline plc: Update following change of outlook to negative

GlaxoSmithKline's credit metrics will remain weak for a prolonged period of time following acquisition of Tesaro

GlaxoSmithKline plc - September 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GlaxoSmithKline plc: Update to credit analysis

A strong business profile partly offset by somewhat weak credit metrics following the buyout of Novartis's stake in consumer health JV

GlaxoSmithKline plc - June 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Damien Conover

Morningstar | GSK Updated Forecasts and Estimates from 17 Jan 2019

GlaxoSmithKline and Pfizer announced the creation of a consumer healthcare joint venture (followed by the potential separation of the entity), which we expect will drive better synergies and unlock value for both companies, but we don't expect any significant changes to our fair value estimates for either company. The companies expect close to GBP 500 million in cost synergies, which seems reasonable. Additionally, we believe the potential separation of the new joint venture could unlock value for both Pfizer and Glaxo, as consumer healthcare companies trade at higher valuation multiples than ...

Eric Le Berrigaud

GLAXOSMITHKLINE: GSK makes long-awaited move to split the group in two parts | NEUTRAL | 1660p vs. 1620p

GLAXOSMITHKLINE - NEUTRAL | 1660p vs. 1620p (+10%) GSK makes long-awaited move to split the group in two parts The future exit of CHC is a good way to deleverage Pharma A positive move but some concerns remain An accretive deal to partially offset dilution from Tesaro Back to our figures before Tesaro. Slight increase of our FV

Martial Descoutures ...
  • Pierre Corby

GlaxoSmithKline : Diversification no longer the favoured option

>Creating a world leader in OTC through a joint venture with Pfizer - Scale is key in the consumer business. GSK and Pfizer yesterday set out plans to create a new global consumer company combining the OTC operations of the two groups. GSK is expected to own 68% of this new entity and Pfizer 32%. The combination is set to bring together a diversified portfolio of products in high-volume therapeutic areas, for global sales of $ 12.7bn in 2017 (pain relief with Advil an...

Martial Descoutures ...
  • Pierre Corby

GlaxoSmithKline : Une diversification qui n’a plus la côte

>Création du leader mondial de l’OTC via une JV avec Pfizer - Avoir une taille critique est clé dans le Consumer. Aussi, GSK et Pfizer annonçaient hier leur volonté de créer une nouvelle « global consumer company » afin de combiner les activités OTC des deux sociétés. GSK détiendrait ainsi 68% de cette nouvelle entité et Pfizer, 32%. La société proposerait ainsi un portefeuille de produits diversifié dans des aires thérapeutiques à fort volume pour des ventes globales...

Damien Conover

Morningstar | Glaxo and Pfizer Form Consumer Joint Venture to Create Synergies and Unlock Underlying Value

GlaxoSmithKline and Pfizer announced the creation of a consumer healthcare joint venture (followed by the potential separation of the entity), which we expect will drive better synergies and unlock value for both companies, but we don't expect any significant changes to our fair value estimates for either company. The companies expect close to GBP 500 million in cost synergies, which seems reasonable. Additionally, we believe the potential separation of the new joint venture could unlock value for both Pfizer and Glaxo, as consumer healthcare companies trade at higher valuation multiples than ...

1 director sold

A director at GlaxoSmithKline sold 30,000 shares at 1,604p and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Eric Monnier

Top Picks Q2 Healthcare: From five names down to three

The least we can say about Q1 2018 is that it was another tough quarter for healthcare in general with few exceptions across the sector, despite early activity on the M&A front with Sanofi announcing the acquisitions of Bioverativ and Ablynx in January. This was not enough to prevent the sector from underperforming the general indices by 1.4pp (-6% in absolute terms). We assume this is mainly the reflection of shy 2018 guidance on average from most companies suggesting in the end another transition year with very limited growth, most of which coming from the positive impact of the US tax refor...

Jean Sassus ...
  • Martial Descoutures
  • Pierre Corby
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/20/2018

Following the Oddo BHF cognac seminar held in November 2018, we are adopting a cautious view of the cognac market. After a clear acceleration in growth for the past two years, the market seems increasingly risky in the short term and its downturn would have clear repercussions on earnings growth for all spirits groups. Even though cognac is a prized asset for them, in that it guarantees a high valuation for the long term due to its scarcity value and high-end profile, we reiterate our...

Jean Sassus ...
  • Martial Descoutures
  • Pierre Corby
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 20/12/2018

...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/14/2018

...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/12/2018

...

François Maury ...
  • Georges Dieng
  • Jerôme Bodin
  • Johanna Jourdain
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Philippe Ourpatian
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/11/2018

...

Nurhayati Wan

GlaxoSmithKline Plc

Nurhayati Wan

GlaxoSmithKline Plc

Nurhayati Wan

GlaxoSmithKline Plc

Nurhayati Wan

GlaxoSmithKline Plc

Nurhayati Wan

GlaxoSmithKline Plc

GlobalData Department

GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile

Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including...

GlobalData Department

GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including...

Dominic Rose ...
  • Naresh Chouhan

New Asthma Drugs Set to Sell $10bn

Five new drugs will drive the Severe Uncontrolled Asthma market from $4bn today to $10bn by 2023. Our bottom-up model shows that biologic drug penetration could almost double by 2023. We see AZN and Sanofi as material winners in the space and show that consensus is likely too low on Tezepelumab, Fasenra & Dupixent. Fasenra is already winning against Nucala (GSK), the P3 Dupixent asthma data has gone underappreciated and consensus models just $200m for Teze in 2023 in AZN numbers.

Dominic Rose ...
  • Naresh Chouhan

Revenue Downgrade Cycle Almost Over

Persistent revenue downgrades have led to investor concern around future analyst forecasts, particularly for new drugs. Our analysis shows that the causes of the sector revenue downgrades have been largely driven by Primary Care launches in the US. More importantly, we show that the downside risk to future new product forecasts has fallen materially. We argue that if forecasts are now more accurate, the recent Pharma sell-off creates a good entry point.

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 04/05/2017

Sir Andrew Witty will be stepping down as CEO with effect from 31 March 2017 and will be succeeded by Emma Walmsley. Dr Patrick Vallance joined the Board in his role as President, R&D on 1 January 2017. Item 2: Approve the Remuneration Report. The remuneration structure is unsatisfactory. Variable remuneration has the potential to be excessive and the actual awards exceeded guidelines. Item 15: Re-appoint the Auditor. PricewaterhouseCoopers LLP (PwC) have been the Group

Jérôme VINERIER

Analyse court terme - GLAXOSMITHKLINE : La tendance est incertaine.

La tendance est incertaine. Les cours se sont repris, mais la tendance manque de puissance pour le moment. La prochaine résistance est à 1 625,00 p.

Jérôme VINERIER

Short term view - GLAXOSMITHKLINE : The trend is uncertain.

The trend is uncertain. Prices have recovered but the trend lacks power for the time being. The next resistance is at 1,625.00 p.

Jérôme VINERIER

Short term view - GLAXOSMITHKLINE : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 1,560.00 p. Breaking below the support at 1,318.00 p would invalidate the trend.

Jérôme VINERIER

Analyse court terme - GLAXOSMITHKLINE : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 1 560,00 p. La rupture du support à 1 318,00 p invaliderait cette tendance.

Jérôme VINERIER

Medium term view - GLAXOSMITHKLINE : The background trend is clearly bullish.

The background trend is clearly bullish. The correction is gaining traction. It is too early to qualify this action as a bearish reversal. The trend would be invalidated below the support at 1,321.00 p.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch